Veritas In Silico Inc. (TSE: 130A)
Health Care · Life Sciences Tools & Services · JP
¥426.00
-1.84% today · -36.1% 1Y
Veritas In Silico Inc. (TSE: 130A) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $17.45M and employs 19 people.
Over the last twelve months the share price has lost 36.1%, trading between 390.00 and 793.00.
Tweenvest scores Veritas In Silico Inc. across four factors: quality 44/100, value 36/100. Its strongest factor is quality.
130A price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.45M
- Revenue (TTM)
- $519.36K
- P/E
- —
- EPS
- -96.78
- Dividend yield
- —
- Beta (5Y)
- -0.27
- 52-week high
- ¥793.00
- 52-week low
- ¥390.00
- Avg volume (3M)
- —
- Shares outstanding
- 6.49M
- Employees
- 19
- Next earnings
- —
About Veritas In Silico Inc.
Veritas In Silico Inc. engages in the development of molecular medicine drugs. It provides a platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. The company was founded by Shingo Nakamura on November 17, 2016 and is headquartered in Tokyo, Japan.
- ISIN
- JP3155340007
- Founded
- 2016
- Listed since
- Feb 8, 2024
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Genolution Inc.KOSDAQ: A225220 | $19.41M | ₩1,444.00 | -1.70% |
| Promimic AB (publ)OM: PRO | $18.42M | Skr9.60 | -1.54% |
| OncoSil Medical LimitedASX: OSL | $17.93M | AU$0.70 | -11.39% |
| Oxford BioDynamics PlcAIM: OBD | $17.79M | £0.00 | -13.04% |
| Jeevan Scientific Technology LimitedBSE: 538837 | $17.35M | Rs83.60 | -1.31% |
| Bionano Genomics, Inc.NasdaqCM: BNGO | $16.90M | $1.31 | -8.71% |
| Fusion Antibodies plcAIM: FAB | $16.56M | £0.10 | -2.50% |
| Proteomics International Laboratories LtdASX: PIQ | $14.43M | AU$0.13 | +4.17% |
Figures last refreshed Oct 11, 2026.